Objective: To compare clinical value of different biomarkers (CK19,hMAM,SBEM) used to detect circulating tumor cells(CTCs) in peripheral blood of patients with breast cancer using real-time quantitative PCR (QPCR) platform. Methods: The expression of CK19,hMAM,SBEM in human breast cancer cell lines MCF-7 was detected by real time QPCR,peripheral blood samples of 20 healthy volunteers and 20 patients with breast benigh disease were detected to identify the base line expression of CK19,hMAM,SBEM. The expression of CK19,hMAM,SBEM in peripheral blood from 94 patients with operable breast cancer was detected also. Results: CK19,hMAM and SBEM were all detected in MCF-7,and the Ct value were 13.87,34.47,and 20.14,respectively;among the 40 control persons,one sample expressed CK19,one sample expressed hMAM,and no sample expressed SBEM;among the 94 patients with operable breast cancer,46 (49%) samples expressed CK19,32 (34%) samples expressed hMAM,and 12(13%) samples expressed SBEM,53 (56%) samples were positive by combined detection using the three biomarkers. Conclusion: It is higher sensitivity to detect circulating tumor cells in peripheral blood of breast cancer combined detection using multimarkers(CK19,hMAM,SBEM) based on a real time QPCR platform,yet specificity was not depressed.